Recursion Pharmaceuticals (RXRX) Operating Leases (2022 - 2026)

Recursion Pharmaceuticals has reported Operating Leases for 5 years, with the latest figure at $42.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 23.53% year-over-year to $42.8 million; the trailing twelve-month figure through Mar 2026 stood at $42.8 million (down 23.53% YoY), and the FY2025 full-year result was $46.6 million, down 30.64% from the prior year.
• Operating Leases for Q1 2026 stood at $42.8 million, down from $46.6 million in the prior quarter.
• The five-year high for Operating Leases was $88.8 million in Q2 2024, with the low at $42.8 million in Q1 2026.
• Historically, Operating Leases has averaged $51.6 million across 5 years, with a median of $47.8 million in 2022.
• Annual changes were most pronounced in 2024 — Operating Leases soared 73.82% — and 2025, when it sank 39.85%.
• Recursion Pharmaceuticals' Operating Leases stood at $44.4 million in 2022, then fell by 2.26% to $43.4 million in 2023, then soared by 54.9% to $67.2 million in 2024, then sank by 30.64% to $46.6 million in 2025, then retreated by 8.16% to $42.8 million in 2026.
• The last three Operating Leases figures came in at $42.8 million (Q1 2026), $46.6 million (Q4 2025), and $50.0 million (Q3 2025), per Business Quant data.